SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 7, 2004
-----------
PROGENICS PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
---------------------------- ----------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
-------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
--------------
-------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
EXHIBIT NUMBER DESCRIPTION
Exhibit 99.1 Press Release dated May 7, 2004 of the Company announcing
its results of operations for its first quarter and three
months ended March 31, 2004 (filed herewith).
Item 12. Results of Operations and Financial Condition.
The Company furnishes its press release dated May 7, 2004, in which the
Company announces, among other things, its results of operations for its first
quarter and for the three months ended March 31, 2004. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ Philip K. Yachmetz
--------------------------
Philip K. Yachmetz
Vice President, General Counsel and Secretary
Date: May 24, 2004